nal permeability demonstrated in critically ill patients is associated with an increased incidence of bacteria and toxin translocation from the intestinal lumen to the systemic circulation, causing infectious complications including sepsis and the multiple organ failure syndrome (MOFS) (1, 2) . This possibility was first explored by Ziegler et al. (3) , who measured the urinary excretion of an orally ingested mixture of lactulose and mannitol (4) and demonstrated that the intestinal permeability of burn patients increases with the presence of infection (lactulose/mannitol ratio ϭ 0.113 Ϯ 0.033 among burn patients with infection vs. 0.035 Ϯ 0.005 among healthy persons). At the time of the study, noninfected burn patients had lactulose/ mannitol ratios equal to those of healthy persons (0.036 Ϯ 0.007). Despite its originality and importance, the study had some limitations. Few patients were studied (n ϭ 15) and they were evaluated only 15 Ϯ 4 days (noninfected burn patients) and 18 Ϯ 5 days (infected burn patients) after the burn. It was not clear whether the burn injury caused the increase of the intestinal permeability, whether the increase of intestinal permeability caused systemic infections, or whether the systemic infections increased the intestinal permeability.
One of these questions was clarified by Deitch (5) , who demonstrated that paracellular intestinal permeability (lactulose/mannitol ratio) of patients with burns covering Ͼ20% of their body surface, in stable hemodynamic condition and without infection, is increased within 24 hrs after the injury (0.052 Ϯ 0.011 among burn patients vs. 0.017 Ϯ 0.002 among healthy persons); that is, the situation of severe burn per se increases intestinal permeability. In addition, Le Voyer et al. (6) showed that burn patients who developed clinical infections within 2-14 days after the injury had a significantly greater increase in intestinal permeability (lactulose/mannitol ratio ϭ 0.208 Ϯ 0.02) than burn patients who did not develop infection (lactulose/mannitol ratio ϭ 0.082 Ϯ 0.02) and than control healthy subjects (lactulose/mannitol ratio ϭ 0.017 Ϯ 0.003).
The relationship between intestinal permeability and systemic infections was clarified by Faries et al. (7) , who demonstrated that on the fourth day after admission, patients with multiple traumatic injuries present a significant correlation between increased intestinal permeability and all indexes of injury severity used (AS-COT, Trauma and Injury Severity Score, Injury Severity Score, RTS, and Acute Physiology and Chronic Health Evaluation II). Compared with patients with moderately increased intestinal permeability (lactulose/mannitol ratio of 0.030 -0.100, n ϭ 18), patients with markedly increased intestinal permeability (lactulose/mannitol ratio Ն0.100, n ϭ 11) presented a higher frequency of the systemic inflammatory response syndrome (SIRS, 83% vs. 44%), infectious complications (58% vs. 13%), and MOFS (55% vs. 17%). Similar results were obtained by Doig et al. (8) when they compared the increase of intestinal permeability (lactulose/mannitol ratio) of 47 critically ill patients with the development of MOFS. The increase in intestinal permeability was the only variable predictive of MOFS among the 28 patients (60% of the sample) who developed this complication. In addition, the intensity of the increase of intestinal permeability was associated with the severity of MOFS, as assessed by the classification system of Marshall et al. (9) . The patients who developed MOFS continued to have increased intestinal permeability, presenting a significant delay in its normalization compared with patients who did not.
In view of the results of these studies, we conclude that severe injury per se (5) and the presence of infection (6) are associated with increased intestinal permeability and that, the greater the intensity (7) and duration of the increase in intestinal permeability (8) , the greater the severity of the clinical signs and symptoms of the patients and the risk of the onset of infectious complications, SIRS, and MOFS.
In contrast to these studies demonstrating an association between increased intestinal permeability and systemic infections, other laboratories have not demonstrated this association (10 -13) . The data in Table 1 provide an analysis of studies that obtained both positive and negative results. The following criteria were satisfied by most of the studies that demonstrated an association between increased intestinal permeability and systemic infections: a) a relatively large number of patients were studied; b) inclusion/exclusion criteria for the patients under study were well defined; c) the patients were better stratified regarding the severity of injury and/or the intensity of the increase in intestinal permeability; d) conditions were established to increase the accuracy of the test measuring intestinal permeability, such as better pairing of patients with controls, use of the ratio of the urinary excretion of two specific markers, and determination of reference values for the geographic region in which of the population under study resides (14) ; e) the urine samples were refrigerated and/or bacteriostatic agents were added during and/or immediately after the execution of the permeability test; f) two or more measurements of intestinal permeability were performed for the same patient at different times; and g) similar mannitol excretion values were obtained for the healthy controls and for the patients under study since the intestinal permeability for mannitol (transcellular) is not altered by injury and/or infection (15) . On the basis of the considerations summarized in Table 1 , it is clear that those studies whose results demonstrated an association between intestinal permeability and systemic infections had a better design and used better controls than those whose results did not.
BACTERIAL TRANSLOCATION
Can the translocation of bacteria and toxins from the intestinal lumen to the systemic circulation explain the association between increased intestinal permeability and systemic infections in critically ill patients? In clinical practice, critically ill patients frequently present bacteremia, sepsis, or MOFS in the absence of an identifiable focal point of infection. Goris et al. (16) demonstrated that no septic focus was detected clinically or even at autopsy in 31 patients (34% of the sample) with bacteremia who developed clinical sepsis or MOFS. This observation is consistent with the view that the intestine is a reservoir of bacteria and of bacterial products (endotoxins, exotoxins, and cell wall fragments) that may escape from the intestinal lumen to the mesenteric lymph nodes, bloodstream, and inner organs (1, 17) . In critically ill patients, the intestine is believed to be not only the target but also the site responsible for the production of inflammatory mediators that may contribute to the installation of SIRS as well as bacteremia, sepsis, or MOFS (8, 18, 19) . The risk of infectious complications caused by enteric bacteria is higher among patients with ischemia/reperfusion of the intestine after a cardiopulmonary bypass (20) or hemorrhagic shock (21); among patients with intestinal obstruction (22) , immunosuppression (23) , or malnutrition (24) ; and among alcoholic patients with cirrhosis (25) .
Bacterial translocation has been demonstrated directly in laboratory animals on the basis of monitoring bacterial migration using tissue histology, microbial culture of internal organs, and dissemination of specifically labeled intestinal bacteria (26 -28) . In humans, there are a limited amount of data demonstrating intestinal bacterial translocation (for reviews, see Refs. 17, 29, 30) . Recovery of viable enteric bacteria from mesenteric lymph nodes is considered by some to be one of the most sensitive direct methods to demonstrate gut barrier failure and bacterial translocation (1, 31) , but others argue that is not clear whether positive nodes merely represent a normal immunogenic event or reflect some form of a morbid state (17, 18 ).
An increase of gut wall permeability measured by tracers (e.g., lactulose/ mannitol) was considered by Redl et al. (32) to be an indirect demonstration of bacterial translocation. The adequacy of lactulose and mannitol as probes for the measurement of intestinal permeability in humans has been validated by the demonstration that 100% of these intravenously administered markers are recovered in the urine and by the fact that the distribution volumes and patterns of excretion of these markers are virtually identical and the oxidation of intravenously administered mannitol accounts for only about 1% of the dose (33) . Recently some of the assumptions underlying the differential sugar permeability test have been questioned (34) . For example, healthy rats submitted to fluid loading present an increased lactulose/ rhamnose ratio independent of changes in intestinal permeability (35) . Furthermore, the diffusion of markers across rat colonic mucosa is directional and temperature-dependent, suggesting that active processes are involved (36) . These contradictory results may reflect only differences between species or tissues, and further investigation is necessary.
The methods used to demonstrate the translocation of intestinal bacteria in lab-oratory animals usually cannot be applied to humans (32) . However, the results of several clinical studies have demonstrated that bacteria isolated from patients with systemic infections are often of the same strain as bacteria predominantly present in the fecal flora (37) , that Gram-negative bacteria present in the intestine often are the agents responsible for infectious complications in high-risk hospitalized patients (38) , and that enteric bacteria which presumably have translocated are sometimes recovered from the mesenteric lymph nodes of high-risk patients submitted to surgery (39) . In addition, the incidence of infectious complications can be reduced by the administration of antibiotics for selective decontamination of the gastrointestinal tract (40, 41) , and other therapeutic measures directed at intestinal dysfunction also improve the prognosis of critically ill patients (for reviews, see Refs. 42, 43) . This favorable patient response can be explained by the reduced production of proinflammatory factors after intestinal injury and by the reduction of the expression of virulence genes of the bacteria of the intestinal flora. The interactions between microbes and enterocytes can be modified by circulating stress hormones (for reviews, see Refs. 44, 45) . The expression of PA-1 lectin/ Procedures executed Urine refrigeration and later freezing at Ϫ20°C (6) Addition of triethanolamine buffer (7) Addition of gentamicin and 10% thymol (8) No report of the measures used for urine conservation during or immediately after the test (12) No. of measurements of intestinal permeability 2 or more measurements (6-8) One measurement (11) ICU, intensive care unit; TRISS, Trauma and Injury Severity Score; ISS, Injury Severity Score. The numbers in parentheses are reference numbers.
adhesin, a key virulence determinant of experimental Pseudomonas aeruginosa gut-derived sepsis, may be induced in mice submitted to surgical stress (46) . Furthermore, strains of cecal Escherichia coli harvested from stressed mice after hepatectomy-starvation present major adherence and reduce the transepithelial electrical resistance of cultured mouse colon cells (47) . Wells and Erlandsen (31) suggested that, although the available data provide only circumstantial evidence, they are consistent with the view that the translocation of bacteria from the intestinal lumen to the systemic circulation is responsible for the development of bacteremia and sepsis in critically ill patients. More recently, however, the clinical relevance of bacterial translocation in humans has been questioned (19) and even rejected (44) . In a study by Moore et al. (48) , 20 critically ill patients were analyzed after major torso trauma (13 patients with blunt trauma and seven patients with penetrating trauma), some of them in a state of shock at the time of hospitalization (systolic blood pressure Ͻ90 torr in 12 patients, i.e., 60% of cases), who required emergency laparotomy. Among these patients, the presence of bacteria was rarely detected in portal vein blood cultures (eight positive cultures among 212 carried out on blood samples obtained during laparotomy and then 6, 12, 24, and 48 hrs and 5 days after (48) has been used as an argument to question the view that bacterial and/or toxin translocation is the primary or sole cause of the development of MOFS after intestinal ischemia/reperfusion (19, 44) . However, damage to the physiologic intestinal barrier permits the adherence and/or internalization of intestinal bacteria by cells of the intestine (49, 50) . The early translocation of bacteria and/or toxins to the intestinal wall may trigger SIRS and dysfunction of distant organs by activating the intestinal inflammatory response, even when the translocated bacteria are destroyed by the immunologic and nonimmunologic cells of the intestine. Under these conditions, the intestine could become a producer of cytokines and other proinflammatory factors and the mesenteric microcirculation the site of activation of circulating neutrophils (19) . On the other hand, late bacterial translocation due to the break of the intestinal barrier induced by many factors in immunodeficient hosts and in injured patients who are terminal on ar- 51 Cr EDTA ϭ 2.32 Ϯ 0.77% (n ϭ 7) 51 Cr EDTA ϭ 2.29 Ϯ 0.67% (n ϭ 7) Before glutamine administration 51 Cr EDTA ϭ 3.26 Ϯ 2.15% (n ϭ 7) 51 Cr EDTA ϭ 2.27 Ϯ 1.32% (n ϭ 7) After glutamine administration for 4 wks Placebo-Glicine No significant Increased permeability was defined as a 6-hr cumulative excretion Ͼ 1.1% of the dose of 51 Cr-EDTA rival may lead to bacteremia, sepsis, and MOFS (18) . The view that the intestinal lymphatics are the principal pathway for toxic or proinflammatory factors produced by the intestine and that subsequently reach the systemic circulation is supported by clinical and experimental data. Lymphatic mesenteric nodules are the first and frequently the only tissue to present a positive culture for enteric bacteria (19, 29) , and elevated levels of endotoxin of intestinal origin have been identified in the thoracic duct before their subsequent detection in the portal circulation (51) . Recently it has been shown that unidentified biologically active factors are present in the mesenteric lymph, but not the portal plasma, of rats with intestinal injury induced by hemorrhagic shock or burns (52) . These substances are toxic for endothelial cells and activate neutrophils, conditions that can lead to gut-origin organ failure. The ligation of the mesenteric lymphatic duct minimizes or inhibits the installation of pulmonary injury induced by hemorrhagic shock in primates (53) . In humans, the translocation of lymphatic bacteria and toxins has been rarely studied. In a study developed in intensive care patients, Lemaire et al. (54) presented evidence for endotoxin translocation beyond the mesenteric lymph nodes into the thoracic duct, but differences in endotoxin concentrations in lymph and blood were not demonstrated between patients with and without MOFS, and the quantity of endotoxin transported by the thoracic duct was low (41-63 units/L). However, the lymph cytokines and cytokine-receptor-antagonist levels were higher in the MOFS group. These results with patients add further support to the experimental studies indicating that the intestine could become a proinflammatory organ and that nonbacterial factors produced in the intestine and present in mesenteric lymph can contribute to distant organ injury.
These interpretations reconcile the results of apparently contradictory studies, identifying the role of the intestine as the principal organ responsible for the production of inflammatory mediators of SIRS and for the installation of MOFS, despite the demonstration of negative cultures of portal vein blood from patients with MOFS. Although at present there is no direct demonstration of bacterial translocation from the intestinal lumen to the systemic circulation and only limited evidence for the translocation of intestinal endotoxins to the lymphatic circulation in humans, it is probable that intestinal bacteria and toxins may trigger, maintain, and exacerbate the SIRS and MOFS in patients with dysfunction of the physiologic intestinal barrier.
INTESTINAL BARRIER
The physiologic intestinal barrier is formed primarily by the mechanical cell barrier and by intercellular junctions, by the immunologic barrier, by the normal microbial flora, and by the liver-intestine axis (55) . Alterations in all of these components of the intestinal barrier have been reported to be responsible for bacterial and toxin translocation (56) . The failure of the intestinal barrier is primarily characterized by impaired nutrient absorption, compromised intestinal immunologic response, and increased intestinal permeability (1, 2). An increase of intestinal permeability has been demonstrated in critically ill patients admitted to intensive care units due to diverse clinical conditions (8, 10) , in patients exposed to burns (3, 5, 6) , in patients submitted to cardiopulmonary bypass (20) , in victims of severe polytraumatic injury (7, 11) , in recipients of bone marrow transplantation (57) , and in alcoholics with cirrhosis (25) .
The increase of intestinal mucosa permeability is triggered by a set of changes such as oxidative stress with increased production of nitric oxide and its derivatives, release of proinflammatory cytokines, reduction of intramucosal pH, and hypoxia (58, for a review see Ref. 59 ). The increase in intestinal permeability is closely related to the presence of mucosal ischemia (60) . In situations of increased metabolic rate secondary to sepsis and other critical illnesses, the cells of the intestinal mucosa require increased oxygen. Paradoxically, in these situations there is a reduction in oxygen availability to values below critical levels due to the reduction in oxygen release and extraction by intestinal mucosal cells (61) . Intracellular oxygen concentrations that are inadequate to support normal mitochondrial respiration induce anaerobic glycolysis with adenosine triphosphate depletion and intracellular acidosis, factors that predispose an increase in the permeability of the intestinal mucosa (62) . The injury to the mucosa caused by ischemia may be aggravated by reperfusion, probably by activation of the xanthine oxidase pathway causing an increased formation of reactive oxygen species such as superoxide anion (63) . Free radicals derived from oxygen cause additional microcirculatory disorders by injuring endothelial cells and activating neutrophils, which in turn generate more reactive oxygen species (61) . These alterations result in increased damage to the tissue microcirculation with exacerbation of the ischemic intestinal injury and of the increase in intestinal permeability (64, 65) .
In clinical situations and experimental models associated with increased paracellular epithelial permeability, the intercellular tight junction is the target of injury. Tight junctions and paracellular epithelial permeability are controlled physiologically by intracellular mediators probably by modulation of the actin-based cytoskeletal ring (for reviews, see Refs. 66, 67) . However, in the presence of systemic inflammation in response to infusion of lipopolysaccharide to mice, there is an increase in the activity of the induced form of nitric oxide synthase causing a generalized dysfunction of epithelial tight junctions, as has been demonstrated in the intestine (68), liver (69) , and lungs (70) . Similar results have been demonstrated in human colonic Caco-2 and HT29 c1.19A cell monolayers with combinations of cytokines containing interferon-␥ (e.g., interferon-␥, interleukin-1␤, and tumor necrosis factor-␣) (71, 72) . The effects of cytokines are potentiated under acidic conditions (73) and in the presence of superoxide radical anion (72) because of an increase in nitric oxide conversion to products with a greater oxidation power such as peroxynitrite and peroxynitrous acid (74, 75) . These potent oxidants damage cellular DNA and promote the peroxidation of lipid membranes, the oxidation of several essential molecules such as thiols and ascorbate, the inactivation of mitochondrial aconitase, and the down-regulation of the expression of several key tight junction proteins of the ileum and colon (68, 76, 77) . Changes in the cytoskeleton of enterocytes, associated with increased adherence and paracellular transmigration of Proteus mirabilis, E. coli, and Enterococcus gallinarum (49, 50) , have been demonstrated after exposure of monolayers of Caco-2 intestinal cells to the toxins of Clostridium difficile (49) , to ethanol (76) , and to cytochalasin (78) . Furthermore, in rats exposed to burns it has been shown that the reduction of peroxynitrite levels by the inhibition of the induced form of nitric oxide synthase by S-methylisothiourea reduces the translocation of intestinal bacteria to mesenteric lymph nodes (four of ten vs. 11 of 11), to the liver (two of ten vs. ten of 11), and to the spleen (zero of ten vs. six of 11) (79) .
The clinical implication of the demonstration that in the presence of intramucosal acidosis the toxic subproducts of nitric oxide and the cytokines increase the intestinal permeability is that goaldirected therapy using gastric tonometry, together with the administration of vasoactive drugs and antioxidants, may preserve intestinal permeability (74) . Inotropic agents that improve splanchnic perfusion by adjusting blood flow and oxygen supply to metabolic needs (e.g., dobutamine) and the avoidance of agents that redistribute blood away from the intestinal mucosa may maintain paracellular intestinal permeability and mucosal integrity in patients with injury (for reviews, see Refs. 60, 80). Furthermore, it has been demonstrated in monolayers of Caco-2 intestinal cells that agents that scavenge peroxynitrite or diminish the formation of peroxynitrite from nitric oxide and superoxide radical attenuate the deleterious effects of both peroxynitritegenerating systems and ethanol (76, 81) . Antioxidants such as N-acetylcysteine, reduced glutathione, L-cysteine, and glutamine also limit the production of peroxynitrite and peroxynitrous acid, reducing the production of superoxide radicals and the increase in intestinal permeability (74, 76) . In laboratory animals exposed to intestinal ischemia/ reperfusion it has been shown that intravenous glutamine infusion partially maintains the levels of intestinal glutathione and reduces cellular membrane lipidic peroxidation (82) .
EFFECT OF GLUTAMINE ON INTESTINAL PERMEABILITY
Glutamine and Intestinal Permeability. The results obtained evaluating the effects of glutamine on intestinal permeability have been variable and depend primarily on the duration of administration and the dose (83, 84, for a recent review see Ref. 85 ). An important aspect of the experimental design is when glutamine administration is started in relation to the occurrence of the injury. Some investigators have demonstrated that glutamine administered before (86) or immediately after (87-89) the occurrence of the injury prevents the increase in intestinal permeability. A different protocol is used by investigators who want to determine whether an established increase in intestinal permeability is reduced or eliminated by glutamine administration (90, 91) . These experimental protocols provide different information, and therefore we propose that the results of studies that evaluate the relationship between glutamine and intestinal permeability be analyzed in terms of the "protective" effect of glutamine that prevents and/or minimizes an acute increase in intestinal permeability and of the "therapeutic" effect of glutamine on a chronically established increase in intestinal permeability (Table 2) .
Clinical and animal studies have demonstrated that the administration of glutamine before or immediately after surgery, burns, or the administration of parenteral nutrition has a protective effect, preventing and/or reducing the intensity of the increase in intestinal permeability (Table 2 ). Jiang et al. (87) , in a prospective, double-blind, multiplecenter study conducted on 120 patients submitted to major elective abdominal surgery, demonstrated that the addition of 0.50 g/kg/day of the alanine-glutamine dipeptide (equivalent to 0.34 g glutamine/kg/day) to the parenteral nutrition solution for 6 days minimized the intensity of the increase of intestinal permeability during the postoperative period. In this study, the lactulose/mannitol ratio was 0.058 Ϯ 0.049 vs. 0.047 Ϯ 0.029 before surgery and 0.097 Ϯ 0.063 vs. 0.132 Ϯ 0.081 (p ϭ .02) on the seventh postoperative day in the patients of the glutamine and control groups, respectively. The patients who received glutamine presented a better cumulative nitrogen balance and were hospitalized for a shorter period of time (12.5 days, i.e., 4 days less than the control group), and no patient developed infection in the surgical incision (three patients in the control group presented infectious complications). Similar results were obtained by Zhou et al. (88) , who demonstrated that the increase in intestinal permeability of 20 patients exposed to severe burns, as demonstrated by the lactulose/mannitol method on the first day after injury, was reduced (third day), normalized (sixth day), and maintained normal (twelfth day) by the administration of an enteral diet supplemented with glutamine dipeptide at the dose of 0.5 g/kg/day (equivalent to 0.34 g L-glutamine/kg/day) for 11 days. The patients in the glutamine group also presented significantly better wound healing (86 Ϯ 2% complete vs. 72 Ϯ 3% complete on day 30, p ϭ .041) and a reduction of the duration of hospitalization (67 Ϯ 4 days vs. 73 Ϯ 6 days, p ϭ .026). Peng et al. (89) confirmed and extended these results by reporting that the accentuated increase in intestinal permeability of 25 patients exposed to severe burns was reduced by the oral administration of 0.5 g/kg/day glutamine "granules" (Chongqing Yao You Pharmaceuticals). In this study, the lactulose/ mannitol ratio was 0.25 Ϯ 0.06 vs. 0.26 Ϯ 0.09 before treatment and 0.12 Ϯ 0.09 vs. 0.20 Ϯ 0.06 (p Ͻ .01) after glutamine treatment for 14 days in the patients of the glutamine and control groups, respectively (lactulose/mannitol ratio ϭ 0.03 Ϯ 0.01 for control healthy subjects). The patients treated with glutamine also presented the largest reduction of plasma diamine oxidase activity ( In addition to these results, van der Hulst et al. (86) demonstrated that the administration of total parenteral nutrition with the addition of the dipeptide glycyl-L-glutamine (0.23 g glutamine/kg/ day for patients receiving 1.56 g protein/ kg/day) prevented exacerbation of the increase in intestinal permeability (lactulose/mannitol) in patients with chronic intestinal inflammatory disease or with intestinal neoplasias. All patients who received total parenteral nutrition without the addition of glutamine presented exacerbation of the increase in intestinal permeability.
In contrast to its positive "protective" effect in acute situations of high permeability, administration of pharmacologic doses of glutamine (Ն20 g/day, see Refs. 92, 93) has essentially no effect on the chronic increase in intestinal permeability (Table 2 ). Noyer et al. (90) assessed the effect of low doses of orally administered glutamine (4 g/day, 0.062 g/kg/day or 8 g/day, 0.124 g/kg/day, for 28 days) on the chronic increase in intestinal permeability (lactulose/mannitol) of patients with AIDS. In this study, the patients who had received a placebo (n ϭ 8) or 4 g of glutamine/day (n ϭ 8) presented an increase in intestinal permeability. Among the patients who received 8 g of glutamine/day (n ϭ 8), intestinal permeability remained high but with no further increase. Similar results were obtained by Den Hond et al. (91) , who, after administering 7 g of glutamine by the oral route, three times a day for 4 wks to seven patients with Crohn's disease with high intestinal permeability ( 51 Cr-EDTA), failed to demonstrate a significant reduction in the increased intestinal permeability, in the index of inflammatory activity of the disease, or the increase in plasma glutamine levels. These results can be explained by the fact that low doses of glutamine (90) were administered by the oral route to patients who presumably present a reduction of intestinal absorptive capacity (90, 91) . However, it is also possible that the mechanisms responsible for the increase of intestinal permeability associated with chronic disease are different from those associated with acute injury and are not responsive or are less responsive to glutamine treatment.
Most of the successful applications of the administration of pharmacologic doses of glutamine to critically ill patients (83) (84) (85) have used the intravenous route because it permits a more effective postoperative recovery of serum glutamine levels in patients submitted to surgery (94) , and it is particularly indicated for patients with reduced intestinal absorptive capacity. The question of the route of administration and the dose of glutamine should be evaluated cautiously because the oral administration of larger amounts of glutamine in an attempt to obtain a "therapeutic" effect may be ineffective or even harmful if the decision is made to maintain the total amount of nitrogen administered per day while reducing other protein sources that provide essential amino acids (95) or alternatively to increase the total amount of nitrogen administered per day to unreasonable levels (96) . This problem is also present when large amounts of glutamine are administered intravenously in the form of a dipeptide, which contains glutamine plus the nonessential amino acids alanine or glycine. One hundred milliliters of the commercial product Dipeptiven (Fresenius Kabi, Bad Homberg, Germany) contains 20 g of N (2)-L-alanyl-L-glutamine, which corresponds to 8.20 g of L-alanine and 13.46 g of L-glutamine. Consider a critically ill patient weighing 70 kg who should receive 1.5 g of protein/kg/day, that is, 105 g of protein/day (16.8 g of nitrogen). If we administer 30 g of glutamine/day (5.8 g of nitrogen) we will also administer 18.3 g of alanine (2.9 g of nitrogen). This implies that other proteins corresponding to only 8.1 g of nitrogen (i.e., 50.6 g of other protein sources that supply essential amino acids) will need to be administered. This final amount of protein obtained from other sources (Ͻ1.0 g of protein/kg) is less than that currently recommended for critically ill patients (1.5 g/kg/day, Ref.
97).
The apparent superiority of intravenous administration of glutamine (85) must be reevaluated because it recently has been shown that the enteral administration of the alanyl-glutamine dipeptide (88) or glutamine "granules" (89) is effective in reducing the increase of intestinal permeability in burn patients presumably with intact intestinal absorptive capacity. Although the question of enteral vs. parenteral administration requires more investigation, it is possible that the ineffectiveness of enteral diets enriched with glutamine on the reduction of intestinal permeability of critically ill patients (98, 99 ) is related to the usual difficulties of delivering enteral diets, with subsequent reduction in the dose of glutamine administered, the delay in initiating the administration of enteral diet (e.g., by the presence of adynamic ileum) (100) , and the effect of other pharmacologic nutrients such as arginine and -3 fatty acids in the immune-enhancing diets. Recently it has been demonstrated that arginine increases nitric oxide production and intestinal permeability in critically ill patients (59, 75) . These considerations about the route of glutamine administration are not just academic. The dipeptide and amino acids administered intravenously are at least 100 times more expensive than enteral or oral glutamine administration.
Results obtained in clinical studies suggest that intravenous administration of glutamine before (86) or immediately after the installation of a situation of injury (87) , in doses of about 0.34 g of glutamine/kg/day, corresponding to 0.50 g of the dipeptide alanine-glutamine/kg/day, has a "protective" effect by preventing or reducing the intensity of the increase in intestinal permeability. Positive effects on the reduction of the increase of intestinal permeability have also been demonstrated by the enteral administration of pharmacologic doses of glutamine in the form of dipeptide (88) or "granules" (89) to patients with acute injury. On the basis of these considerations we recommend the administration of glutamine as a pharmacologic supplement adjunct to primary therapy for patients exposed to situations of acute and severe injury, in doses of about 0.34 g/kg/day. Furthermore, this glutamine should not be calculated as part of the patient's nutritional protein intake. At present it is not possible to conclude if glutamine has a "therapeutic" effect on a chronically established increased intestinal permeability. In the few studies in which this question was considered, the patients received an insufficient dose of glutamine (90) by the oral route (90, 91) even though they may have had reduced intestinal absorptive capacity.
Glutamine, Bacterial Translocation, and Systemic Infections. The effect of glutamine to preserve or recover intestinal barrier function, thus reducing translocation and the systemic dissemination of intestinal bacteria, has been demonstrated in laboratory animals submitted to different types of injury, such as burns (28) , methotrexate (101), or radiation (102) . The administration of enteral diets enriched with glutamine maintains the intestinal barrier (102) ; reduces the extent of bacterial translocation to mesenteric lymph nodes and improves the ability to kill translocated E. coli bacteria (28) ; reduces the dissemination of bacteria to the liver, spleen, blood, and lung; and reduces mortality rate (28, 101) .
No study has been conducted thus far on humans using methods such as mesenteric lymph node culture demonstrating the effects of glutamine supplementation on the translocation of intestinal bacteria (for reviews, see Refs. 17, 30). Although there is no consensus in the literature (103) , it has been demonstrated in several clinical studies that glutamine administration reduces the number of infections in critically ill patients with SIRS (98) and in patients with multiple trauma (104) , reduces the frequency of P. aeruginosa infections (105) and of Gramnegative bacteremia in patients exposed to severe burns (106) , and reduces the frequency of Candida infections and the mortality caused by them, with improved survival during a period of 6 months after admission to the intensive care unit (84) . Although these results may be related to an improvement of the immunologic response of glutamine-supplemented patients (107, for a review, see Ref. 108) , it is also possible, although not confirmed, that glutamine reduces the translocation of intestinal bacteria in humans. Consistent with this interpretation is the fact that intravenous administration of the dipeptide L-alanyl-L-glutamine (0.3 g/kg/ day) to critically ill patients prevents the 
